345 related articles for article (PubMed ID: 33864145)
1. Cancer Treatment-Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy.
Diana A; Carlino F; Giunta EF; Franzese E; Guerrera LP; Di Lauro V; Ciardiello F; Daniele B; Orditura M
Curr Treat Options Oncol; 2021 Apr; 22(5):45. PubMed ID: 33864145
[TBL] [Abstract][Full Text] [Related]
2. Challenges in Preventing Bone Loss Induced by Aromatase Inhibitors.
Rachner TD; Göbel A; Jaschke NP; Hofbauer LC
J Clin Endocrinol Metab; 2020 Oct; 105(10):. PubMed ID: 32674135
[TBL] [Abstract][Full Text] [Related]
3. Management of bone loss due to endocrine therapy during cancer treatment.
Khan MI
Osteoporos Int; 2023 Apr; 34(4):671-680. PubMed ID: 36656338
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Options for the Management of Aromatase Inhibitor- Associated Bone Loss.
Gaudio A; Xourafa A; Rapisarda R; Castellino P
Endocr Metab Immune Disord Drug Targets; 2022; 22(3):259-273. PubMed ID: 34370654
[TBL] [Abstract][Full Text] [Related]
5. Antiresorptive agents' bone-protective and adjuvant effects in postmenopausal women with early breast cancer.
Chukir T; Liu Y; Farooki A
Br J Clin Pharmacol; 2019 Jun; 85(6):1125-1135. PubMed ID: 30536446
[TBL] [Abstract][Full Text] [Related]
6. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
Ito K; Blinder VS; Elkin EB
J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
[TBL] [Abstract][Full Text] [Related]
8. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
[TBL] [Abstract][Full Text] [Related]
9. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
Hadji P; Aapro MS; Body JJ; Bundred NJ; Brufsky A; Coleman RE; Gnant M; Guise T; Lipton A
Ann Oncol; 2011 Dec; 22(12):2546-2555. PubMed ID: 21415233
[TBL] [Abstract][Full Text] [Related]
10. [ RANKL antibody for treatment of cancer treatment-induced bone loss (CTIBL)].
Takahashi S
Clin Calcium; 2011 Aug; 21(8):1239-47. PubMed ID: 21814031
[TBL] [Abstract][Full Text] [Related]
11. The role of bisphosphonates in the adjuvant setting for breast cancer.
Reeder JG; Brufsky AM
Oncology (Williston Park); 2010 May; 24(6):462-7, 475. PubMed ID: 20568587
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with bone-targeted agents.
Wilson C; Coleman RE
Curr Opin Support Palliat Care; 2011 Sep; 5(3):241-50. PubMed ID: 21785355
[TBL] [Abstract][Full Text] [Related]
13. Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.
Tremblay D; Patel V; Fifer KM; Caro J; Kolodka O; Mandelli J; Shapiro CL
Support Care Cancer; 2018 Jan; 26(1):197-202. PubMed ID: 28744736
[TBL] [Abstract][Full Text] [Related]
14. Cancer-treatment-induced bone loss, part 2.
Michaud LB; Goodin S
Am J Health Syst Pharm; 2006 Mar; 63(6):534-46. PubMed ID: 16522890
[TBL] [Abstract][Full Text] [Related]
15. Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: position statement summary.
Grossmann M; Ramchand SK; Milat F; Vincent A; Lim E; Kotowicz MA; Hicks J; Teede HJ
Med J Aust; 2019 Sep; 211(5):224-229. PubMed ID: 31318068
[TBL] [Abstract][Full Text] [Related]
16. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
Brufsky A
Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial.
Gnant M; Pfeiler G; Dubsky PC; Hubalek M; Greil R; Jakesz R; Wette V; Balic M; Haslbauer F; Melbinger E; Bjelic-Radisic V; Artner-Matuschek S; Fitzal F; Marth C; Sevelda P; Mlineritsch B; Steger GG; Manfreda D; Exner R; Egle D; Bergh J; Kainberger F; Talbot S; Warner D; Fesl C; Singer CF;
Lancet; 2015 Aug; 386(9992):433-43. PubMed ID: 26040499
[TBL] [Abstract][Full Text] [Related]
18. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
[TBL] [Abstract][Full Text] [Related]
20. Osteoporosis management in patients with breast cancer: EMAS position statement.
Trémollieres FA; Ceausu I; Depypere H; Lambrinoudaki I; Mueck A; Pérez-López FR; van der Schouw YT; Senturk LM; Simoncini T; Stevenson JC; Stute P; Rees M
Maturitas; 2017 Jan; 95():65-71. PubMed ID: 27802892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
